RxSight affirms 2025 outlook as CFO transition arrangements set

RxSight, Inc. reported that it has entered into a transition agreement and release of claims, as well as a consulting agreement, with its outgoing Chief Financial Officer and principal financial and accounting officer, Shelley Thunen.

Rhea-AI Filing Summary

RxSight, Inc. reported that it has entered into a transition agreement and release of claims, as well as a consulting agreement, with its outgoing Chief Financial Officer and principal financial and accounting officer, Shelley Thunen. Under these agreements, she will provide certain transition services to support the company after her employment separation date.

The company stated that this Chief Financial Officer leadership transition does not affect its outlook or expectations for full-year 2025. RxSight also noted that it continues to execute on its strategic and operational priorities, indicating that its business plans and financial expectations remain intact despite the change in its finance leadership.

Insights

Equity analyst focused on medical technology companies

RxSight formalizes its CFO transition while affirming its full-year 2025 outlook.

RxSight, Inc. detailed a transition agreement and consulting agreement with outgoing Chief Financial Officer Shelley Thunen, under which she will continue providing transition services after her separation date. This structure typically aims to maintain continuity in financial reporting, planning, and investor communications during a leadership handoff.

The company explicitly stated that the Chief Financial Officer leadership transition does not affect its outlook or expectations for full-year 2025 and that it continues to execute against its strategic and operational priorities. That language signals that, based on current information, management does not view the change in its finance leadership as altering its business trajectory or internal plans.

For investors, the key disclosed elements are the formalization of Ms. Thunen’s transition and consulting roles and the reiteration of the existing full-year 2025 outlook. Subsequent company filings may provide additional detail on the new finance leadership structure and any further compensation or governance changes tied to this transition.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did RxSight, Inc. (RXST) disclose?

RxSight, Inc. disclosed that its Chief Financial Officer and principal financial and accounting officer, Shelley Thunen, is undergoing a previously announced leadership transition supported by a transition agreement and a consulting agreement.

How will Shelley Thunen remain involved with RxSight (RXST) after her separation?

RxSight and Shelley Thunen entered into a transition agreement and release of claims and a consulting agreement, effective as of her employment separation date, under which she will provide certain transition services to the company.

Does the CFO transition change RxSight’s outlook for full-year 2025?

RxSight stated that the leadership transition of its Chief Financial Officer does not affect the company’s outlook or expectations for full-year 2025 and that it continues to execute against its strategic and operational priorities.

Where can investors find more details on the RxSight CFO transition agreements?

RxSight referenced a prior disclosure and noted that the full text of the Transition Agreement and Consulting Agreement is expected to be filed as exhibits to a subsequent periodic report with the U.S. Securities and Exchange Commission.

What forward-looking statements did RxSight (RXST) highlight in this update?

RxSight’s forward-looking statements include its outlook or expectations for full-year 2025 and statements about its expectations and outlook as it continues to execute on its strategic and operational priorities, all subject to risks and uncertainties described in its SEC filings.

Are the RxSight outlook comments in this update considered filed for liability purposes?

The company stated that the information referenced under Item 7.01, including any related exhibit, shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/23/2025 - 05:21 PM Learn about SEC filing dates

false000111148500011114852025-12-232025-12-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 23, 2025

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40690	94-3268801
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the previously announced pending transition of Shelley Thunen from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), on December 23, 2025, RxSight, Inc. (the “Company”) and Ms. Thunen entered into a transition agreement and release of claims (the “Transition Agreement”) and a consulting agreement, effective as of her employment separation date, pursuant to which she will provide certain transition services for the Company (the “Consulting Agreement”). For more information regarding the material terms of the Transition Agreement and Consulting Agreement, see Item 5.02 of the Current Report on Form 8-K filed by the Company on December 22, 2025, which is incorporated herein by reference. Such description of the material terms of the Transition Agreement and the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Transition Agreement and the Consulting Agreement, which the Company expects to file as exhibits to a subsequent periodic report to be filed with the U.S. Securities and Exchange Commission (the “SEC”).

Item 7.01. Regulation FD Disclosure.

The Company reports that the leadership transition of its Chief Financial Officer, as described in Item 5.02 of this Current Report on Form 8-K, does not affect the Company’s outlook or expectations for full-year 2025, and the Company continues to execute against its strategic and operational priorities.

This report contains forward-looking statements, including statements concerning Company’s outlook or expectations for full-year 2025 and statements relating to the Company’s expectations and outlook as it continues to execute on its strategic and operational priorities. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in our Quarterly Report on Form 10-Q for the three months ended September 30, 2025, filed with the SEC on November 5, 2025, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this report to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

The information referenced under Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			RxSight, Inc.
Date:	December 23, 2025	By:	/s/ Ron Kurtz, M.D.
			Ron Kurtz, M.D. Chief Executive Officer and President